Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Shigeki Nanj"'
Autor:
Yuki Sato, Yoshiharu Sato, Kei Irie, Shigeki Nanjo, Shigeo Hara, Satoru Fujiwara, Keisuke Tomii
Publikováno v:
Thoracic Cancer, Vol 15, Iss 23, Pp 1772-1775 (2024)
Abstract We present the case of a 34‐year‐old Japanese man with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer and brain metastases. After central nervous system (CNS) disease progression with alecintib and brigatinib, t
Externí odkaz:
https://doaj.org/article/9dda332cfb6e4c8c9d4fe688ccdf5463
Autor:
Tej D. Azad, Shigeki Nanjo, Michael C. Jin, Jacob J. Chabon, David M. Kurtz, Aadel A. Chaudhuri, Ian D. Connolly, Angela Bik-Yu Hui, Chih Long Liu, David Merriott, Ryan Ko, Christopher Yoo, Justin Carter, Emily Chen, Rene Bonilla, Akito Hata, Nobuyuki Katakami, Kei Irie, Seiji Yano, Ross Okimoto, Trever G. Bivona, Aaron M. Newman, Michael Iv, Seema Nagpal, Melanie Hayden Gephart, Ash A. Alizadeh, Maximilian Diehn
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-10 (2024)
Abstract Cerebrospinal fluid tumor-derived DNA (CSF-tDNA) analysis is a promising approach for monitoring the neoplastic processes of the central nervous system. We applied a lung cancer-specific sequencing panel (CAPP-Seq) to 81 CSF, blood, and tiss
Externí odkaz:
https://doaj.org/article/eaae1e7a290d44c69e031450a6628a56
Autor:
Franziska Haderk, Yu-Ting Chou, Lauren Cech, Celia Fernández-Méndez, Johnny Yu, Victor Olivas, Ismail M. Meraz, Dora Barbosa Rabago, D. Lucas Kerr, Carlos Gomez, David V. Allegakoen, Juan Guan, Khyati N. Shah, Kari A. Herrington, Oghenekevwe M. Gbenedio, Shigeki Nanjo, Mourad Majidi, Whitney Tamaki, Yashar K. Pourmoghadam, Julia K. Rotow, Caroline E. McCoach, Jonathan W. Riess, J. Silvio Gutkind, Tracy T. Tang, Leonard Post, Bo Huang, Pilar Santisteban, Hani Goodarzi, Sourav Bandyopadhyay, Calvin J. Kuo, Jeroen P. Roose, Wei Wu, Collin M. Blakely, Jack A. Roth, Trever G. Bivona
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alt
Externí odkaz:
https://doaj.org/article/be0a7eca3725431ab19bfe58739629b9
Autor:
Akihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, Hiroshi Kotani, Kaname Yamashita, Koushiro Ohtsubo, Shigeki Nanjo, Seiji Yano, Keishi Mizuguchi, Hiroko Ikeda, Shinji Takeuchi
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
We report a case of limited effectiveness of dabrafenib and trametinib in a 59-year-old man with poorly differentiated lung carcinoma and a rare BRAF K601E mutation. The patient, unresponsive to chemotherapy and immunotherapy, received these targeted
Externí odkaz:
https://doaj.org/article/67c78e62172b42b580e93f5cade774a9
Autor:
Kouji Izumi, Hiroaki Iwamoto, Hiroshi Yaegashi, Takahiro Nohara, Kazuyoshi Shigehara, Yoshifumi Kadono, Shigeki Nanjo, Tadaaki Yamada, Koshiro Ohtsubo, Seiji Yano, Atsushi Mizokami
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 4, Pp 831-842 (2021)
Abstract Background Hypogonadism associated with cancer is reported to cause cachexia and a variety of physical and psychological symptoms. This study aims to evaluate whether androgen replacement therapy can improve cancer‐related symptoms in male
Externí odkaz:
https://doaj.org/article/ae73b11679694191a7cfbbc9b105d707
Autor:
Shigeki Nanjo, Wei Wu, Niki Karachaliou, Collin M. Blakely, Junji Suzuki, Yu-Ting Chou, Siraj M. Ali, D. Lucas Kerr, Victor R. Olivas, Jonathan Shue, Julia Rotow, Manasi K. Mayekar, Franziska Haderk, Nilanjana Chatterjee, Anatoly Urisman, Jia Chi Yeo, Anders J. Skanderup, Aaron C. Tan, Wai Leong Tam, Oscar Arrieta, Kazuyoshi Hosomichi, Akihiro Nishiyama, Seiji Yano, Yuriy Kirichok, Daniel S.W. Tan, Rafael Rosell, Ross A Okimoto, Trever G. Bivona
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 13 (2022)
Molecularly targeted cancer therapy has improved outcomes for patients with cancer with targetable oncoproteins, such as mutant EGFR in lung cancer. Yet, the long-term survival of these patients remains limited, because treatment responses are typica
Externí odkaz:
https://doaj.org/article/2ab24c64ef0a4efabc727bb6d4218018
Autor:
Daisuke Ishikawa, Shinji Takeuchi, Takayuki Nakagawa, Takako Sano, Junya Nakade, Shigeki Nanjo, Tadaaki Yamada, Hiromichi Ebi, Lu Zhao, Kazuo Yasumoto, Takahiro Nakamura, Kunio Matsumoto, Hiroshi Kagamu, Hirohisa Yoshizawa, Seiji Yano
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e62104 (2013)
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, is a critical problem in the treatment of EGFR mutant lung cancer. Several mechanisms, including bypass signaling by hepatocyte growth fac
Externí odkaz:
https://doaj.org/article/2a4ca02dcdca49eb800aab4aeeb60dfd
Autor:
Shigeki Nanjo, Tadaaki Yamada, Hiroshi Nishihara, Shinji Takeuchi, Takako Sano, Takayuki Nakagawa, Daisuke Ishikawa, Lu Zhao, Hiromichi Ebi, Kazuo Yasumoto, Kunio Matsumoto, Seiji Yano
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e84700 (2013)
Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects against EGFR mutant lung cancer, patients ultimately develop resistance by multiple mechanisms. We therefore assessed the ability of combined treatment with the M
Externí odkaz:
https://doaj.org/article/fdc6f65bea464645bc4bd7970e319ea3
Autor:
Manasi Mayekar, Deborah Caswell, Natalie Vokes, Emily K. Law, Wei Wu, William Hill, Eva Gronroos, Andrew Rowan, Maise Al Bakir, Clare Weeden, Caroline E. McCoach, Collin M. Blakely, Nuri Alpay Temiz, Ai Nagano, Daniel L. Kerr, Julia K. Rotow, Oriol Pich, Franziska Haderk, Michelle Dietzen, Carlos Martinez Ruiz, Bruna Almeida, Lauren Cech, Beatrice Gini, Joanna Przewrocka, Chris Moore, Miguel Murillo, Bjorn Bakker, Brandon Rule, Cameron Durfee, Shigeki Nanj, Lisa Tan, Lindsay K. Larson, Prokopios P. Argyris, William L. Brown, Johnny Yu, Carlos Gomez, Philippe Gui, Rachel I. Vogel, Elizabeth A. Yu, Nicholas J. Thomas, Subramanian Venkatesan, Sebastijan Hobor, Su Kit Chew, Nicholas McGranahan, Nnennaya Kanu, Eliezer M. Van Allen, Julian Downward, Reuben S. Harris, Trever Bivona, Charles Swanton
Publikováno v:
Cancer Research. 82:2197-2197
Introduction: Increasing our understanding of drivers of mutagenesis in lung cancer is critical in our efforts to prevent tumor reoccurrence and resistance. Results: Using the multi-region TRACERx lung cancer study, we uncovered that APOBEC3B is sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93c49478ed5c7c84f95d81176cd804c0
https://doi.org/10.1158/1538-7445.am2022-2197
https://doi.org/10.1158/1538-7445.am2022-2197